These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 23239736)

  • 1. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
    Xu K; Wu ZJ; Groner AC; He HH; Cai C; Lis RT; Wu X; Stack EC; Loda M; Liu T; Xu H; Cato L; Thornton JE; Gregory RI; Morrissey C; Vessella RL; Montironi R; Magi-Galluzzi C; Kantoff PW; Balk SP; Liu XS; Brown M
    Science; 2012 Dec; 338(6113):1465-9. PubMed ID: 23239736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
    Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
    Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
    Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
    Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
    Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
    Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
    Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
    Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
    Bohrer LR; Chen S; Hallstrom TC; Huang H
    Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
    Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
    Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.
    Daures M; Ngollo M; Judes G; Rifaï K; Kemeny JL; Penault-Llorca F; Bignon YJ; Guy L; Bernard-Gallon D
    OMICS; 2016 Feb; 20(2):123-5. PubMed ID: 26871869
    [No Abstract]   [Full Text] [Related]  

  • 9. Going beyond Polycomb: EZH2 functions in prostate cancer.
    Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
    Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
    Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
    Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
    J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer.
    Nouruzi S; Tabrizian N; Zoubeidi A
    Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
    Chinaranagari S; Sharma P; Chaudhary J
    Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
    Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
    Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations and deletions of PRC2 in prostate cancer.
    Jain P; Di Croce L
    Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
    Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
    J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2, an epigenetic driver of prostate cancer.
    Yang YA; Yu J
    Protein Cell; 2013 May; 4(5):331-41. PubMed ID: 23636686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
    Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
    Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.